Pfizer Inc. (PFE) — closed signal from March 1, 2026
Partial Published before the outcome was known, scored automatically when the window closed on May 30, 2026.
Predicted vs. what happened
What happened
Reached 33% of the predicted growth at its peak, without hitting the target.
The thesis — published March 1, 2026
Pfizer may stage a short-term rebound because March 1 trial results with Astellas give investors a new story around its cancer work. This could pull buyers back in, but the recovery is not yet proven. Treat trades as cautious entries bought on small pullbacks with tight rules, since the stock can fall quickly if buyers lose interest.
Primary drivers
- Trial news can bring new interest and media attention
- Buying on dips lets you add in planned stages near price floors
- Large healthcare firms often steady a portfolio during chaos
- Turnaround moves can reverse fast if buyers disappear
How it played out
PFE: thesis rose some, but missed the target
Lyra published PFE at $27.65 for a short-term window from 2026-03-01 to 2026-05-30. The thesis expected 12% growth and pointed to March 1 trial results with Astellas, a possible rebound in cancer work, staged buying near price floors, and the risk that the move could reverse fast if buyers left.
Inside the window, PFE peaked at $28.75 on 2026-04-02. That was a 4% gain, but it stayed below the $30.97 target. It never got there. By 2026-05-30, it ended at $26.18. The thesis partially played out on direction, then missed on follow-through.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.